Randomized controlled trial （RCTs） of Wuling caspule combined with Deanxit in the treatment of post-stroke depression were searched from CNKI，VIP，WanFang，PubMed and other datebases by electronic computer， and the deadline was September 2020.After the two researchers independently screened the literature， extracted the data and comprehensively evaluated the risk of bias included in this study， a Meta-analysis was performed on all the results using the Revnew 5.3 software.

A total of 23 RCTs were included， including 2059 patients （1033 patients in the experimental group and 1026 patients in the control group）.Meta-analysis results showed that the total effective rate of PSD patients in the experimental group was higher than that in the control group， with statistical significance （RR = 1.19，95%CI：1.14～1.24，P < 0.01）.The Hamilton depression scale （HAMD） score of patients with PSD reduction in the experimental group was significantly higher than that of the control group and was statistically significant （MD = －4.74，95%CI：－5.13～－3.75，P < 0.01）.The NIHSS score of patients with reduced PSD in the experimental group was higher than that in the control group and was statistically significant （MD = －2.33， 95% CI： －3.63～－1.02，P < 0.01）.The Barthel index （BI） score of patients with increased PSD in the experimental group was higher than that of the control group and was statistically significant （MD = 7.09， 95% CI： 4.78～9.41，P < 0.01）.The incidence of adverse reactions in the experimental group was significantly lower than that in the control group and was statistically significant （RR = 0.54，95% CI：0.41～0.70，P < 0.01）.

Compared with Deanxit， Wuling capsule combined with Deanxit can significantly improve the curative effect of PSD， improve the neurological function， daily life ability， and have fewer side effects.